Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × MCRC × regorafenib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 35 Carcinoma, Hepatocellular 14 Rectal Neoplasms 8 Neoplasm Metastasis 8 Colonic Neoplasms 7 Gastrointestinal Stromal Tumors 6 Ovarian Neoplasms 5 Sarcoma 4 Melanoma 4 Osteosarcoma 3 Glioblastoma 3 Cholangiocarcinoma 3 Stomach Neoplasms 2 Pancreatic Neoplasms 2 Liver Neoplasms 2 Gallbladder Neoplasms 2 Fatigue 2 Colorectal Cancer Metastatic 2 Carcinoma, Renal Cell 2 Carcinoma, Non-Small-Cell Lung 2 Bile Duct Neoplasms 2 Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer) 1 Thyroid Neoplasms 1 Thymoma 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Rhabdomyosarcoma 1 Noonan Syndrome 6 1 Neoplasms 1 Multiple Myeloma 1

Interventions

tislelizumab 1 regorafenib 1 Trace amine-associated receptor 1 1 Thymalfasin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06829355 2025-02-17

THYMI

Beijing Friendship Hospital

Phase 2 Recruiting

MCRC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡